Ignite Creation Date:
2024-05-06 @ 8:01 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06229366
Status:
RECRUITING
Last Update Posted:
2024-04-23
First Post:
2024-01-03
Brief Title:
Ac-225-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
Sponsor:
Organization:
POINT Biopharma a wholly owned subsidiary of Eli Lilly and Company